FDA on breakthrough therapy requests by status 2019
This statistic displays the share of FDA statuses of breakthrough therapy requests in the United States in 2019. As of end-September of that year, 46 percent of requests had been denied. The FDA recommends that submissions for breakthrough therapy designations should be made prior to phase III.
